BEIJING: With the help of Insilico Medicine’s research and development team in Shanghai, the globally leading AI-driven biotech company has condensed preclinical drug development from multiple years into just 18 months. “Shanghai is our first choice to design new medicine, as it’s the center of biopharmaceutical innovation,” said Alex Zhavoronkov, founder and CEO of Insilico. “What’s more, there are so …